A

Amgen

Makes biotech medicines for serious illnesses

Senior Manager - Value Strategy & Marketing

Full-TimeUpdated on 10/24/2026
$168k - $227.4k
Senior
Bachelor's, Master's, MBA, PharmD, Associate's
Thousand Oaks, CA, USA
RemoteRemote role; 5–10% travel may be required.
Growth & MarketingProduct Marketing

About the job

Requirements
  • A master's degree and 6 years of directly related experience, or a bachelor's degree and 8 years of directly related experience, or an associate's degree and 10 years of directly related experience, or a high school diploma/GED and 12 years of directly related experience.
  • Strong knowledge of U.S. medical-benefit reimbursement, medical policy, utilization management, and coverage decision making for physician-administered, infused, biologic, specialty, rare-disease, and/or oncology therapies.
  • Demonstrated ability to synthesize complex clinical, economic, real-world, and payer information into differentiated value strategies and clear customer communications.
  • Strong business acumen, analytical skills, strategic thinking, and ability to influence cross-functional partners in a matrixed environment.
  • Demonstrated curiosity and aptitude for generative artificial intelligence and emerging technologies, including the ability to rapidly learn and apply approved tools to solve business problems and improve the quality and speed of work.
  • Strong written, verbal, and presentation skills.
Responsibilities
  • Develop and execute payer value strategies for UPLIZNA and assigned Oncology assets, integrating brand strategy, payer needs, competitive dynamics, reimbursement considerations, and evolving coverage policy.
  • Build and maintain a deep understanding of medical policy, prior authorization, utilization management, buy-and-bill, specialty pharmacy and distribution, site-of-care, and reimbursement dynamics affecting physician-administered therapies.
  • Lead U.S. payer-relevant real-world evidence workstreams with HEOR, CfOR, Medical, Brand, and Insights; contribute payer perspective to study design and objectives to defend coverage, improve quality of coverage, and support appropriate patient identification and treatment.
  • Translate clinical, pharmacoeconomic, real-world, and population-level evidence into differentiated payer value narratives and actionable implications for customer engagement.
  • Identify payer evidence gaps and emerging customer needs and bring clear recommendations into cross-functional evidence-generation and brand-planning discussions.
  • Partner with Market Access and MVPH colleagues to prepare for priority payer and health-system engagements, including customer-specific policy analysis, value messaging, objection handling, and strategic discussion support.
  • Develop and execute payer-facing resources, including payer core visual aids, economic tools, real-world evidence communications, health care economic information and pre-approval information exchange resources where appropriate, payer FAQs, training guides, burden-of-disease resources, and customer-specific materials.
  • Lead materials through the Materials Approval and Compliance process and train and support customer-facing teams on approved value resources.
  • Use approved artificial intelligence tools to accelerate payer policy review, insight synthesis, evidence assessment, strategic development, content creation, and project execution while maintaining human judgment and quality control.
  • Identify and share new artificial-intelligence-enabled use cases that improve the efficiency or quality of Value Strategy & Marketing work while adhering to company policies, data privacy, compliance, and review requirements.
  • Manage agency partners, project timelines, and assigned budgets and ensure work is prioritized against the highest-value payer and access opportunities.
  • Travel 5–10% as required.
Desired Qualifications
  • Direct experience working within or closely with a U.S. health plan, payer organization, medical-benefit manager, or payer-focused healthcare organization is strongly preferred.
  • Experience with buy-and-bill, site-of-care dynamics, reimbursement pathways, and payer management of high-cost specialty therapies.
  • Pharmaceutical or biotechnology market access, payer marketing, value strategy, or reimbursement experience is valued but not required when accompanied by strong direct payer or medical-benefit expertise.
  • Experience interpreting payer coverage policies, claims or reimbursement data, utilization-management trends, or patient-access data to identify barriers and opportunities.
  • An advanced degree such as a Doctor of Pharmacy, Master of Business Administration, or another relevant healthcare or business degree is preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

PR Newswire
Oct 26th, 2026
Amgen appoints former Yum! Brands CEO David Gibbs to its board

Amgen has appointed David W. Gibbs to its board of directors, effective immediately. He will serve on the Audit Committee and the Compensation and Management Development Committee. Gibbs recently retired as president and chief executive officer of Yum! Brands, owner of Taco Bell and Kentucky Fried Chicken. As chief executive from 2020 to 2025, he led its digital transformation and expanded it to nearly 61,000 locations. He has sat on the board of Under Armour since 2021 and PepsiCo since 2026. "His experience creating direct relationships with customers will help inform how we prepare for future launches," said Robert A. Bradway, Amgen's chairman and chief executive officer. The board now has 13 directors, 12 of them independent.

Yahoo Finance
Oct 26th, 2026
ESMO 2026: Moderna vaccine debate, Roche's $3.6B KRAS bet and Amgen's lung cancer data

Three cancer drug trials drew attention at the European Society for Medical Oncology (ESMO) meeting, with investors and analysts weighing the results. Moderna and Merck's vaccine intismeran autogene cut the relative risk of melanoma recurrence or death by 42% in a Phase 3 trial. Moderna's shares have still fallen by double digits since the results leaked early, as investors question its valuation and the vaccine's manufacturing and commercial potential. Roche's divarasib reduced the risk of death or disease progression by 42% in KRAS G12C lung cancer, beating Krazati and Lumakras. Patients lived a median of about 18 months, versus a year. Roche raised its peak sales forecast from 3.6 billion Swiss francs to 3 billion. Amgen's Imdelltra, combined with Imfinzi, cut the risk of death by 58% in small cell lung cancer. Median survival was 21.1 months, against 12.7 months for Imfinzi alone.

Yahoo Finance
Oct 25th, 2026
Amgen vs Gilead: Which biotech dividend stock is the better buy, with yields of 2.2% and 2.1%?

Amgen and Gilead Sciences, two of the few big biotech companies that pay dividends, suit different kinds of income investors, according to a comparison by The Motley Fool's Keith Speights. Amgen offers a forward dividend yield above 2.2%, against slightly below 2.1% for Gilead. Gilead has the lower payout ratio, at 43.5% versus 60.9%, and the cheaper valuation: 15.6 times forward earnings against 16.7. Amgen's product sales grew 9% year over year in its latest quarter, against 8% for Gilead. It has 17 drugs on track to be blockbusters this year, versus eight for Gilead, and 29 late-stage programs. Speights favours Amgen for yield and growth, and Gilead for safety and value.

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.